NCT02781883 - Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML | Biotech Hunter

Enrollment

108

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG

BP1001 in combination with Ventoclax plus decitabine

DRUG

BP1001 plus decitabine

BP1001 plus decitabine in ventoclax intolerant or resistant subjects

Trial Locations (9)

RECRUITING

Laura & Isaac Pe lmutter Cancer Center at NYU Langone Health, New York

RECRUITING

Weill Cornell Medical College - New York - Presbyterian Hospital, New York

TERMINATED

West Virginia University/Mary Babb Randolph Cancer Center, Morgantown

RECRUITING

Georgia Cancer Center at Augusta University, Augusta

RECRUITING

University of Kansas Cancer Center, Fairway

TERMINATED

Baylor Scott & White Research Institute, Temple

RECRUITING

University of Texas M.D. Anderson Cancer Center, Houston

RECRUITING

UCLA Medical Center, Los Angeles

TERMINATED

New Jersey Hematology Oncology Associates, Brick